Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic sclerosis in childhood.

I Foeldvari1

  • 1Senior Consultant Pediatric Rheumatology Clinic, Allgemeines Krankenhaus Eilbek, Haus 6, Friedrichsberger Str. 60, D-22081 Hamburg, Germany. sprechstunde@kinderrheumatologie.de

Rheumatology (Oxford, England)
|September 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort.

Arthritis research & therapy·2025
Same author

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.

Pediatric rheumatology online journal·2021
Same author

Temporomandibular joint involvement in patients with juvenile idiopathic arthritis: a retrospective chart review.

Scandinavian journal of rheumatology·2020
Same author

Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.

Seminars in arthritis and rheumatism·2019
Same author

Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.

Scandinavian journal of rheumatology·2018
Same journal

A conceptual framework for a RA probability score integrating classification criteria and point-of-care ultrasound in early arthritis.

Rheumatology (Oxford, England)·2026
Same journal

Comment on: Single-cell profiling reveals CCL5Hi GZMAHi effector memory CD8 T cell association to oligoarticular juvenile idiopathic arthritis: Reply.

Rheumatology (Oxford, England)·2026
Same journal

Loneliness, traditional risk factor control, genetic predisposition, and development of musculoskeletal disorders.

Rheumatology (Oxford, England)·2026
Same journal

Changing incidence and serotype trends in ANCA-associated vasculitis: a 30-year population-based study in Norfolk, UK.

Rheumatology (Oxford, England)·2026
Same journal

Real-world performance of myositis antibody panels: a single-centre experience.

Rheumatology (Oxford, England)·2026
Same journal

Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials.

Rheumatology (Oxford, England)·2026
See all related articles

Juvenile systemic sclerosis (jSSc) is a rare childhood disease with distinct clinical features and better prognosis than adult forms. Effective treatments require more pediatric-specific research and validated outcome measures.

Area of Science:

  • Pediatric Rheumatology
  • Rare Childhood Diseases
  • Autoimmune Disorders

Background:

  • Juvenile systemic sclerosis (jSSc) is a rare autoimmune condition affecting children.
  • Limited published data exists for jSSc, necessitating further research.
  • jSSc exhibits distinct clinical presentations and organ involvement patterns compared to adult systemic sclerosis.

Purpose of the Study:

  • To summarize current knowledge on juvenile systemic sclerosis.
  • To highlight differences between juvenile and adult systemic sclerosis.
  • To identify gaps in pediatric jSSc research, particularly regarding treatment and outcome measures.

Main Methods:

  • Review of existing literature on juvenile systemic sclerosis.
  • Comparison of clinical features and prognosis between pediatric and adult populations.

Related Experiment Videos

  • Analysis of current research status for outcome measures and treatment efficacy.

    • Main Results:

    • Juvenile systemic sclerosis presents differently from adult-onset disease, with a limited subset of children affected by the limited form.
    • Organ involvement patterns in jSSc differ from those observed in adults.
    • The prognosis for jSSc is notably better, with a 5-year survival rate of 95%.

    Conclusions:

    • Juvenile systemic sclerosis is a distinct entity with a better prognosis than adult systemic sclerosis.
    • Validated outcome measures and pediatric-specific treatment data are crucial for advancing jSSc care.
    • Paediatric rheumatologists currently rely on adult disease data for treatment decisions in jSSc.